|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dubey AK, Gupta U and Jain S: Epidemiology
of lung cancer and approaches for its prediction: A systematic
review and analysis. Chin J Cancer. 35:712016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mathur P, Sathishkumar K, Chaturvedi M,
Das P, Sudarshan KL, Santhappan S, Nallasamy V, John A, Narasimhan
S and Roselind FS; ICMR-NCDIR-NCRP Investigator Group, : Cancer
statistics, 2020: Report from national cancer registry programme,
India. JCO Glob Oncol. 6:1063–1075. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Didkowska J, Wojciechowska U, Mańczuk M
and Łobaszewski J: Lung cancer epidemiology: Contemporary and
future challenges worldwide. Ann Transl Med. 4:1502016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Punturieri A, Szabo E, Croxton TL, Shapiro
SD and Dubinett SM: Lung cancer and chronic obstructive pulmonary
disease: Needs and opportunities for integrated research. J Natl
Cancer Inst. 101:554–559. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sobti RC, Sharma S, Janmeja AK and Jindal
SK: Molecular Pathogenesis of Lung Cancer. Some Aspects of
Chromosome Structure and Functions 2002. Sobit RC, Obe G and Athwal
RS: Springer; Dordrecht: pp. 193–205. 2002, View Article : Google Scholar
|
|
7
|
Massó-Vallés D, Beaulieu ME and Soucek L:
MYC, MYCL, and MYCN as therapeutic targets in lung cancer. Expert
Opin Ther Targets. 24:101–114. 2020. View Article : Google Scholar
|
|
8
|
Burbee DG, Forgacs E, Zöchbauer-Müller S,
Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S,
et al: Epigenetic inactivation of RASSF1A in lung and breast
cancers and malignant phenotype suppression. J Natl Cancer Inst.
93:691–699. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Virno F, Di Giorgio A, Di Lauro G,
Bellezza F and Carrozzini AI: Small cell lung cancer (SCLC) and non
small cell lung cancer (NSCLC): Comparative evaluation of survival
after surgical treatment by computer. Lung Cancer. 2:105–106. 1986.
View Article : Google Scholar
|
|
10
|
Sabari JK, Lok BH, Laird JH, Poirier JT
and Rudin CM: Unravelling the biology of SCLC: Implications for
therapy. Nat Rev Clin Oncol. 14:549–561. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Riihimäki M, Hemminki A, Fallah M, Thomsen
H, Sundquist K, Sundquist J and Hemminki K: Metastatic sites and
survival in lung cancer. Lung Cancer. 86:78–84. 2014. View Article : Google Scholar
|
|
12
|
Brzezniak C, Satram-Hoang S, Goertz HP,
Reyes C, Gunuganti A, Gallagher C and Carter CA: Survival and
Racial Differences of Non-Small Cell Lung Cancer in the United
States Military. J Gen Intern Med. 30:1406–1412. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dong S, Men W, Yang S and Xu S:
Identification of lung adenocarcinoma biomarkers based on
bioinformatic analysis and human samples. Oncol Rep. 43:1437–1450.
2020.PubMed/NCBI
|
|
14
|
Cerfolio RJ, Bryant AS, Scott E, Sharma M,
Robert F, Spencer SA and Garver RI: Women with pathologic stage I,
II, and III non-small cell lung cancer have better survival than
men. Chest. 130:1796–1802. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Moore W, Talati R, Bhattacharji P and
Bilfinger T: Five-year survival after cryoablation of stage I
non-small cell lung cancer in medically inoperable patients. J Vasc
Interv Radiol. 26:312–319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Molassiotis A, Smith JA, Bennett MI,
Blackhall F, Taylor D, Zavery B, Harle A, Booton R, Rankin EM,
Lloyd-Williams M, et al: Clinical expert guidelines for the
management of cough in lung cancer: Report of a UK task group on
cough. Cough. 6:92010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bastarrika G, García-Velloso MJ, Lozano
MD, Montes U, Torre W, Spiteri N, Campo A, Seijo L, Alcaide AB,
Pueyo J, et al: Early lung cancer detection using spiral computed
tomography and positron emission tomography. Am J Respir Crit Care
Med. 171:1378–1383. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lam S, MacAulay C, leRiche JC and Palcic
B: Detection and localization of early lung cancer by fluorescence
bronchoscopy. Cancer. 89 (Suppl):2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wisnivesky JP, Yankelevitz D and Henschke
CI: Stage of lung cancer in relation to its size: part 2. Chest.
127:1136–11369. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ramirez JL, Sarries C, de Castro PL, Roig
B, Queralt C, Escuin D, de Aguirre I, Sanchez JM, Manzano JL,
Margelí M, et al: Methylation patterns and K-ras mutations in tumor
and paired serum of resected non-small-cell lung cancer patients.
Cancer Lett. 193:207–216. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Andriani F, Conte D, Mastrangelo T, Leon
M, Ratcliffe C, Roz L, Pelosi G, Goldstraw P, Sozzi G and Pastorino
U: Detecting lung cancer in plasma with the use of multiple genetic
markers. Int J Cancer. 108:91–96. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mao L, Lee DJ, Tockman MS, Erozan YS,
Askin F and Sidransky D: Microsatellite alterations as clonal
markers for the detection of human cancer. Proc Natl Acad Sci USA.
91:9871–9875. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Belinsky SA: Gene-promoter
hypermethylation as a biomarker in lung cancer. Nat Rev Cancer.
4:707–717. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kwon Y-J, Lee SJ, Koh JS, Kim SH, Lee HW,
Kang MC, Bae JB, Kim YJ and Park JH: Genome-wide analysis of DNA
methylation and the gene expression change in lung cancer. J Thorac
Oncol. 7:20–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao M, Li H, Ma Y, Gong H, Yang S, Fang Q
and Hu Z: Nanoparticle abraxane possesses impaired proliferation in
A549 cells due to the underexpression of glucosamine 6-phosphate
N-acetyltransferase 1 (GNPNAT1/GNA1). Int J Nanomedicine.
12:1685–1697. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bacos K, Gillberg L, Volkov P, Olsson AH,
Hansen T, Pedersen O, Gjesing AP, Eiberg H, Tuomi T, Almgren P, et
al: Blood-based biomarkers of age-associated epigenetic changes in
human islets associate with insulin secretion and diabetes. Nat
Commun. 7:110892016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Furuta E, Okuda H, Kobayashi A and Watabe
K: Metabolic genes in cancer: Their roles in tumor progression and
clinical implications. Biochim Biophys Acta. 1805:141–152.
2010.PubMed/NCBI
|
|
28
|
Aquino-Gil M, Pierce A, Perez-Cervera Y,
Zenteno E and Lefebvre T: OGT: A short overview of an enzyme
standing out from usual glycosyltransferases. Biochem Soc Trans.
45:365–370. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Oikari S, Makkonen K, Deen AJ, Tyni I,
Kärnä R, Tammi RH and Tammi MI: Hexosamine biosynthesis in
keratinocytes: Roles of GFAT and GNPDA enzymes in the maintenance
of UDP-GlcNAc content and hyaluronan synthesis. Glycobiology.
26:710–722. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chu J, Li N and Gai W: Identification of
genes that predict the biochemical recurrence of prostate cancer.
Oncol Lett. 16:3447–3452. 2018.PubMed/NCBI
|
|
31
|
Zhang S, Lu Y, Liu Z, Li X, Wang Z and Cai
Z: Identification Six Metabolic Genes as Potential Biomarkers for
Lung Adenocarcinoma. J Comput Biol. 27:1532–1543. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular profiling of lung adenocarcinoma. Nature.
511:543–550. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Campbell JD, Alexandrov A, Kim J, Wala J,
Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, et
al Cancer Genome Atlas Research Network, : Distinct patterns of
somatic genome alterations in lung adenocarcinomas and squamous
cell carcinomas. Nat Genet. 48:607–616. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wickham H: ggplot2. Wiley Interdiscip Rev
Comput Stat. 3:180–185. 2011. View Article : Google Scholar
|
|
35
|
Sobin LH and Fleming ID: TNM
Classification of Malignant Tumors, fifth edition (1997). Union
Internationale Contre le Cancer and the American Joint Committee on
Cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu H and Zhang J: Decreased expression of
TFAP2B in endometrial cancer predicts poor prognosis: A study based
on TCGA data. Gynecol Oncol. 149:592–597. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES, et al: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Haley JA, Haughney E, Ullman E, Bean J,
Haley JD and Fink MY: Altered Transcriptional Control Networks with
Trans-Differentiation of Isogenic Mutant-KRas NSCLC Models. Front
Oncol. 4:3442014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
R Core Team, . R: A language and
environment for statistical computing. Vienna, Austria.
2013.http://www.R-project.org/
|
|
40
|
Lee W, Jiang Z, Liu J, Haverty PM, Guan Y,
Stinson J, Yue P, Zhang Y, Pant KP, Bhatt D, et al: The mutation
spectrum revealed by paired genome sequences from a lung cancer
patient. Nature. 465:473–477. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Singhal S, Vachani A, Antin-Ozerkis D,
Kaiser LR and Albelda SM: Prognostic implications of cell cycle,
apoptosis, and angiogenesis biomarkers in non-small cell lung
cancer: A review. Clin Cancer Res. 11:3974–3986. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Weinberg RA: Oncogenes and tumor
suppressor genes. CA Cancer J Clin. 44:160–170. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wei Q, Cheng L, Hong WK and Spitz MR:
Reduced DNA repair capacity in lung cancer patients. Cancer Res.
56:4103–4107. 1996.PubMed/NCBI
|
|
44
|
Li M, Zhao H, Zhang X, Wood LD, Anders RA,
Choti MA, Pawlik TM, Daniel HD, Kannangai R, Offerhaus GJ, et al:
Inactivating mutations of the chromatin remodeling gene ARID2 in
hepatocellular carcinoma. Nat Genet. 43:828–829. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kong-Beltran M, Seshagiri S, Zha J, Zhu W,
Bhawe K, Mendoza N, Holcomb T, Pujara K, Stinson J, Fu L, et al:
Somatic mutations lead to an oncogenic deletion of met in lung
cancer. Cancer Res. 66:283–289. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Olivier-Van Stichelen S, Drougat L,
Dehennaut V, El Yazidi-Belkoura I, Guinez C, Mir AM, Michalski JC,
Vercoutter-Edouart AS and Lefebvre T: Serum-stimulated cell cycle
entry promotes ncOGT synthesis required for cyclin D expression.
Oncogenesis. 1:e362012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Steenackers A, Olivier-Van Stichelen S,
Baldini SF, Dehennaut V, Toillon RA, Le Bourhis X, El
Yazidi-Belkoura I and Lefebvre T: Silencing the nucleocytoplasmic
O-GlcNAc transferase reduces proliferation, adhesion, and migration
of cancer and fetal human colon cell lines. Front Endocrinol
(Lausanne). 7:462016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sparreboom A, Scripture CD, Trieu V,
Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M and Desai N:
Comparative preclinical and clinical pharmacokinetics of a
cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and
paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res.
11:4136–4143. 2005. View Article : Google Scholar : PubMed/NCBI
|
